-
Oasmia Pharmaceuticals Says Survival Data From A Phase 3 Study Met Endpoint, Shares Gain 5%
Wednesday, April 27, 2016 - 10:43am | 360Shares of Oasmia Pharmaceutical AB - American Depositary Shares (NASDAQ: OASM), a Sweden-based developer and manufacturer of drugs in the field of human and veterinary oncology, gained more than 5 percent Wednesday after the company reported results from a Phase 3 clinical trial. Oasmia...